Enlivex Therapeutics Ltd. announced that Brian Schwartz, MD, who served for twelve years as Chief Medical Officer of ArQule Inc. and led ArQule’s research and development programs through its $2.7 billion acquisition by Merck earlier this year, joined the Enlivex Board of Directors on November, 15, 2020. Dr. Schwartz brings significant experience in drug development in both the biotechnology and pharmaceutical industries. Dr. Schwartz most recently served as Chief Medical Officer and head of Research and Development of ArQule Inc. where he served as a key member of the management team and spearheaded a number of preclinical and clinical drug development programs in oncology and rare diseases. Prior to joining ArQule in 2008, Dr. Schwartz served as Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm Oncology Inc., where he built and led clinical, regulatory, and quality assurance departments responsible for the development of new cancer drugs.